Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider

In This Article:

As the U.S. stock market experiences fluctuations, with major indices slipping ahead of anticipated comments from Federal Reserve Chair Jerome Powell, investors are keenly observing potential opportunities. Penny stocks, though often considered a relic of past market eras, continue to offer intriguing possibilities for those willing to explore smaller or newer companies with growth potential. By focusing on strong financials and solid fundamentals, these stocks can present affordable entry points into promising ventures in today's dynamic market landscape.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.81915

$6.09M

★★★★★★

RLX Technology (NYSE:RLX)

$1.61

$2.05B

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$161.52M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

AsiaFIN Holdings (OTCPK:ASFH)

$1.50

$81.55M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.40

$125.19M

★★★★★☆

So-Young International (NasdaqGM:SY)

$1.25

$72.53M

★★★★☆☆

ZTEST Electronics (OTCPK:ZTST.F)

$0.2482

$9.05M

★★★★★★

Flexible Solutions International (NYSEAM:FSI)

$4.22

$54.16M

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$0.9278

$87.69M

★★★★★☆

Click here to see the full list of 738 stocks from our US Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

Estrella Immunopharma

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers and solid tumors in the United States, with a market cap of $28.84 million.

Operations: Currently, Estrella Immunopharma does not report any revenue segments.

Market Cap: $28.84M

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company with a market cap of US$28.84 million, remains pre-revenue as it focuses on developing T-cell therapies. Recent news highlights the promising complete response in its STARLIGHT-1 Phase I/II trial without serious adverse events, marking potential progress in its pipeline. However, financial challenges are evident with less than a year of cash runway and ongoing unprofitability. The company's debt-free status is positive, but shareholder dilution and high share price volatility pose risks. Leadership changes bring experienced strategic oversight but may also indicate transitional phases within the company’s governance structure.